Portfolio News
Sofinnova Industrial Biotech
Dr. Neal Gutterson joins Meiogenix board
Paris, July 15, 2022
Meiogenix is pleased to announce that Dr. Neal Gutterson has joined the Meiogenix Board of Directors. Meiogenix’ board chair Johan Cardoen welcomes Dr. Gutterson, noting “Neal has been a very impactful leader in the ag industry, with a strong expertise in biotechnology and genomics. He has been a champion of genome editing and other advanced molecular breeding tools to create new value for farmers and consumers. We look forward to his strategic insights for the Meiogenix board”.
Neal Gutterson noted that, “the industry faces a range of new and increasingly urgent farmer and consumer demands for an improved food system and healthier food. Meiogenix has established a unique technology that excites me in its ability to accelerate delivery of solutions as new cropping systems, new crops and improved sustainability demand more rapid ways to adapt a divderse set of crop varieties.”
Neal joined DuPont Pioneer in 2014. In 2017 when DuPont merged with Dow, he was named Senior Vice President and Chief Technology Officer of the combined entity’s agriculture division, which was subsequently spun off and renamed Corteva Agriscience. There, he led the integration of three research and development organizations into one, developed the new company’s first integrated R&D strategy and oversaw the growth and expansion of its award-winning pipeline. While at Corteva, he championed and brought strategic clarity to the company’s efforts to use its expertise, intellectual property and technologies to address challenges facing smallholder farmers globally.
Prior to joining Corteva, Neal held senior roles with Mendel Biotechnology, rising from Vice President, R&D, to President and Chief Executive Officer. Throughout his career, he has used his scientific expertise and knowledge of organizational design and innovation principles to forge collaborations with organizations of all sizes and stages of maturity. He also spent six years on the Board of the International Maize and Wheat Improvement Center (CIMMYT), along with a number of other associations. He holds a PhD in Biochemistry.
Neal is currently System Board member of the CGIAR, a global research partnership for a food-secure future, and Partner and CTO at Radicle Growth, an early stage sustainable ag and food venture firm.
About Meiogenix
Meiogenix is an agriculture biotech company that develops disruptive new products based on Chromosome Editing. By unlocking the natural genetic diversity of crops, Meiogenix expands the biodiversity that can be used by farmers to address global climate, sustainability and food challenges.
Related News
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
ProQR Therapeutics announces $8.1 million in new funding from Rett Syndrome Research Trust to expand RNA editing collaboration
ProQR appoints Peter A. Beal, PhD, as Chief ADAR Scientist